PT  - JOURNAL ARTICLE
AU  - Haythum O. Tayeb
AU  - Roaa A. Khallaf
AU  - Taim A. Muayqil
AU  - Walid A. Alkeridy
AU  - Fawwaz S. Alibrahim
AU  - Omar A. Alfaify
AU  - Najeeb Qadi
AU  - Frank I. Tarazi
TI  - The future of alzheimer disease immunotherapies in Saudi Arabia: Consensus statement of the Saudi Chapter of Cognitive and Behavioral Neurology
AID  - 10.17712/nsj.2023.2.20220133
DP  - 2023 Apr 01
TA  - Neurosciences Journal
PG  - 77--84
VI  - 28
IP  - 2
4099  - http://nsj.org.sa/content/28/2/77.short
4100  - http://nsj.org.sa/content/28/2/77.full
SO  - Neurosciences (Riyadh)2023 Apr 01; 28
AB  - Alzheimer Disease (AD) constitutes a major global healthcare problem. Standard AD pharmacotherapies offer only modest transient cognitive and behavioral benefits. Aducanumab, an amyloid monoclonal antibody, was the first disease modifying agent to be approved for AD treatment. However, concerns about its efficacy and side effects led regulatory institutions around the world to restrict its use. Lecanemab was the second amyloid antibody to receive accelerated approval for use in early AD. This review and consensus statement was prepared by the Saudi Chapter of Cognitive and Behavioral Neurology to review the current developments in AD immunotherapies from a Saudi perspective. We outline recommendations with regards to offering aducanumab and other future immunotherapies to Saudi AD patients. We describe resources, infrastructure, research, and clinical practice changes that must be attained to transform the patient journey and clinical pathways of AD in Saudi Arabia to enable offering AD immunotherapies in Saudi Arabia.